, Petri M. Iaccarino L et al. , Beresford MW The quantification of reliability is expressed by a correlation coefficient. SLE is an immune-mediated multisystemic disease characterized by a wide variability of clinical manifestations and a course frequently subject to unpredictable flares [1, 2]. The aim of this systematic literature review is to describe and analyse the . , Ibaez D [PDF] Use of Physician Global Assessment in systemic lupus LECTURE 10: MEDICAL SURGICAL NURSING. , Zonana-Nacach A It furthers the University's objective of excellence in research, scholarship, and education by publishing worldwide, This PDF is available to Subscribers Only. Oxford Textbook of. [2, 21, 24] recommended PGA assessment prior to reviewing serological data, based only on the clinical visit. Meta-analysis of the studies reporting data concerning the construct validity between the PGA and SLEDAI. 25 (FIVE YEARS 8) Latest Documents Most Cited Documents Contributed Authors Related Sources Related Keywords Latest Documents; Most Cited Documents; Contributed Authors; Related Sources; , Jolly M. Ribi C The search strategy for SSc-related publications identified 75 citations . The PGA was developed on a 0 to 3 scale as part of the Lupus Activity Index. For your privacy and protection, when applying to a job online, never give your social security number to a prospective employer, provide credit card or bank account information, or perform any sort of monetary transaction. , Petri MA et al. doi:10.1136/ rmdopen-2017-000578 Prepublication history and Additional papers were obtained by checking the references from the selected studies. Physician's global assessment is often useful in SLE - ResearchGate van Vollenhoven R Int J Environ Res Public Health. T2 - A longitudinal study. A good responsiveness for PGA was shown in eight studies. An international panel of 79 SLE experts participated in a three-round Delphi consensus process, in which 41 statements related to the PGA in SLE were . Criterion validity data reporting correlation coefficients between PGA and quality of life measures, laboratory markers and miscellaneous. History of Changes for Study: NCT05672576 Newark, New Castle, USA, March 03, 2023 (GLOBE NEWSWIRE) -- The global complement-targeted therapeutics market is expected to grow at a CAGR of 8.9% from 2022 to 2030, owing to the rising . J Clin Med. Currently no agreement has been reached on which scale should be used: a pointed scale with anchored values (0, 1, 2, 3) or a centimetric scale with all values between 0.0 and 3.0. Barr et al. 8600 Rockville Pike Face validity was reported in all the articles retrieved in which the PGA was used alone or as part of composite indices (Systemic Responder Index, Safety of Estrogen in Lupus Erythematosus National Assessment Flare Index, Lupus Low Disease Activity State, Definitions of Remission in Systemic Lupus Erythematosus criteria). , Cappellazzo G Neuropsychiatry OXFORD TEXTBOOKS IN PSYCHIATRY Oxford Textbook of Neuropsychiatry Edited by Niruj Agrawal, Rafey Faruqui, and Mayur Bodani Oxford Textbook of Psychiatry of Intellectual Disability Edited by Sabyasachi Bhaumik and Regi Alexander Oxford Textbook of Inpatient Psychiatry Edited by Alvaro Barrera, Caroline Attard, and Rob Chaplin Oxford Textbook of Attention . Mina R , Subach RB However, it is important to remember that not all clinical problems reported by a lupus patient are due to the disease. Unable to load your collection due to an error, Unable to load your delegates due to an error. Criterion validity was assessed exploring the PGA correlation with quality of life measurements, biomarker levels and treatment changes in 28 studies, while no study has evaluated correlation with damage. In most studies, the PGA was assessed by a rheumatologist experienced in SLE care or research and, as already stated, the ICC reliability was different for an untrained physician and a trained investigator [36]. Dynabook PX1900E-1NCA, PROTECTIVE SLE (PX1900E-1NCA) 2014 - 20184 years. , Hennis A. Jesus D SLE or at an SLE site, but only if the injury requires treatment by a licensed medical doctor. Cloud, mobility, security, and more. No study has evaluated the correlation of PGA with damage measures. , Dietzmann K , Kalunian K global automatic chemiluminescence immunoassay analyzer market INTRODUCTION The chemiluminescence immunoassay system employs magnetic particle separation technology, which employs magnetic particles as antibody carriers and allows for even distribution of the carriers in the liquid phase reaction system, resulting in a faster and more effective . Liang MH The PGA was introduced in 1998 by a US Food and Drug Administration panel as the preferred tool to assess and record the severity of disease in clinical studies, and typically rates a patient's disease from 'clear' to 'severe' or 'very severe' [1, 2]. The assessment of disease activity in SLE is particularly challenging. , Mohan C. Jolly M , Skogh T Objective Existing methods for grading lupus flares or improvement require definition-based thresholds as increments of change. Systemic Lupus Erythematosus and Lupus Nephritis - Epidemiology , Buyon J , Giangreco D , Matos A Touma Z ~SLE~. , Patrick DL It operates in Albuquerque, and New Mexico. A PGA >1 was predictive of polymorphic light cutaneous eruption (P=0.02) [59] and correlated negatively with LLDAS attainment [37]. Three studies evaluated the association between PGA scores and treatment changes: PGA correlated negatively with adherence to treatment assessed through an item scale (r=0.31, P=0.11) [34]; clinically defined mild and moderate flares had a higher disease activity by the PGA (P<0.001) than those defined as mild/moderate flare only by medication changes [55]; PGA scores were associated positively with response to belimumab treatment (P=0.039) [43]. Associations between physicians' global assessment of disease activity Management of systemic lupus erythematosus (SLE) often depends on disease severity and disease manifestations, [] although hydroxychloroquine has a central role for long-term treatment in all SLE patients. , Chakravarty E Global Respiratory Devices Market Size, Growth, Source Analysis, Top Your recommendations as to what might or should be done in relation to various issues observed. Physician's Global Assessment (PGA) score 1.0 on a 0 to 3 visual analog scale. SELENA SLEDAI4. Construct validity was recognized in 21 studies [2, 10, 11, 23, 24, 2629, 35, 47, 52, 54, 65, 68, 76, 84, 88, 92, 99, 101]. Face validity was reported in all the articles retrieved in which the PGA was used alone or as part of composite indices (Systemic Responder Index, Safety of Estrogen in Lupus Erythematosus National Assessment Flare Index, Lupus Low Disease Activity State, Definitions of Remission in Systemic Lupus Erythematosus criteria). Prinsen CAC This scoring modality was used for the SRI [3]. Unauthorized use of these marks is strictly prohibited. Construct validity was demonstrated by a good correlation (r0.50) between the PGA with the SLEDAI (12 studies), SLAM (4 studies), LAI, BILAG and ECLAM (2 studies each). Content validity was reported in 89 studies. Physician global assessments for disease activity in rheumatoid arthritis are all over the map!. AU - Kasitanon, Nuntana. Improving patient pathways for systemic lupus erythematosus: a multistakeholder pathway optimisation study. et al. When expanded it provides a list of search options that will switch the search inputs to match the current selection. Reviews and case series with fewer than five patients were excluded. et al. , Glassman DS To determine longitudinal associations between Physician Global Assessment (PGA) and patient-reported outcomes (PROs) in patients with systemic lupus erythematosus (SLE). SLE is an autoimmune disease in which the immune system attacks its own tissues, causing widespread inflammation and tissue damage in the affected organs. , OMalley T Results: Different definitions of PGA retrieved through the literature search are reported in Table1. , Adamichou C The interrater reliability (interRR) of the PGA is the ability to provide consistent scores in a stable population between two or more physicians who evaluate the disease activity of the same patient. Criterion validity is defined as the degree to which the scores of an instrument adequately reflect the truth in the form of a gold standard [107]. JSS Medical Research. CLOSED ANGLE/ ANGLE CLOSURE GLAUCOMA. , Urowitz MB Deconstruction of the safety of estrogen in lupus erythematosus national assessment-systemic lupus erythematosus disease activity index flare index, Effect of raloxifene on disease activity and vascular biomarkers in patients with systemic lupus erythematosus: subgroup analysis of a double-blind randomized controlled trial, Omega-3 in SLE: a double-blind, placebo-controlled randomized clinical trial of endothelial dysfunction and disease activity in systemic lupus erythematosus, Erythrocyte sedimentation rate is a predictor of renal and overall SLE disease activity, Characterization of clinical photosensitivity in cutaneous lupus erythematosus, Validation of the systemic lupus erythematosus responder index for use in juvenile-onset systemic lupus erythematosus, Depressive symptoms and associated factors in systemic lupus erythematosus, Validation of the Portuguese simple measure of impact of lupus erythematosus in youngsters (SMILEY) in Brazil, Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers, Performance of anti-C1q, antinucleosome, and anti-dsDNA antibodies for detecting concurrent disease activity of systemic lupus erythematosus, An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA, Noncalcified coronary plaque in systemic lupus erythematosus, Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus, Validity and reliability of lupus activity measures in the routine clinic setting, Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. , Socher SA This is a top barrier, both for treat-to-target management of SLE patients in clinical practice, as well as in clinical trials for new SLE treatments. Physician global assessment in systemic lupus erythematosus: can we Physician global assessments for disease activity in rheumatoid Schlencker A, Messer L, Ardizzone M, Blaison G, Hinschberger O, Dahan E, Sordet C, Walther J, Dory A, Gonzalez M, Kleinlogel S, Bramont-Nachman A, Barrand L, Payen-Revol I, Sibilia J, Martin T, Arnaud L. Lupus Sci Med. , Khamashta MA PGA is a valid, responsive and feasible instrument, though its reliability was impacted by the scale adopted, suggesting the major need for standardization of its scoring. Construct validity is shown by the good correlation observed with the SLEDAI, BILAG, SLAM, LAI and ECLAM [10, 23, 24, 26, 28, 29, 35, 54, 68, 76, 84, 99]. 1 2. 2019ACREULAR . The site is secure. Of note, it is not trivial that we found a good convergent validity with other instruments (SLEDAI, BILAG, LAI, SLAM and ECLAM) [10, 23, 24, 26, 28, 29, 35, 54, 68, 76, 84, 99]. Content validity was reported in 89 studies. This property is reported across all articles selected through this systematic review [24, 913, 21103]. The SRI is a validated SLE disease activity instrument used to detect clinically meaningful improvement of disease in SLE clinical trials. , Merrill JT. , Lau CS A systematic review of the literature was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines [17], searching for articles reporting on the use of PGA in SLE. Impact of anti-SARS-CoV-2 antibodies of different isotypes (IgA, IgG, IgM) on attainment of PGA . , Sayedbonakdar Z Background Physician Global Assessment (PGA) is a visual analogue score (VAS) that reflects the clinician's judgment of overall Systemic Lupus Erythematosus (SLE) disease activity. , McGwin G While specific studies remain to be performed to determine the optimal method for scoring the PGA, this literature search showed that the most adopted form of PGA was a 10cm 03 VAS with anchors (0, none; 1, mild; 2, moderate; 3, severe activity) [3]. et al. 2. Currently the lack of standardized scoring, as well as the subjectivity of the physician judgements, can be an important source of heterogeneity, especially in trials. On stratifying the results by individual clinician, values ranged from 0.61 to 0.90, except for those reported by . Results of a large, multicentric, nationwide study, American College of Rheumatology provisional criteria for global flares in childhood-onset systemic lupus erythematosus, A cross-sectional study of hydroxychloroquine concentrations and effects in people with systemic lupus erythematosus, Inactive disease and remission in childhood-onset systemic lupus erythematosus, Preliminary criteria for global flares in childhood-onset systemic lupus erythematosus, Systemic lupus erythematosus in a multiethnic US cohort, XXXVII: association of lymphopenia with clinical manifestations, serologic abnormalities, disease activity, and damage accrual, Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXIX. Mok CC Treatment of lupus nephritis: consensus, evidence and perspectives PGA - Lupus Research The assessment of PGA responsiveness was performed in 10 studies [4, 23, 50, 58, 7779, 81, 83, 84] using different methods [110]. Patient and Physician Global Assessments of Disease Status in Systemic Methods This SLR was conducted by two independent reviewers in accordance with the PRISMA statement. , Klein-Gitelman MS Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus. , Hynan LS Elisabetta Chessa, Matteo Piga, Alberto Floris, Herv Devilliers, Alberto Cauli, Laurent Arnaud, Use of Physician Global Assessment in systemic lupus erythematosus: a systematic review of its psychometric properties, Rheumatology, Volume 59, Issue 12, December 2020, Pages 36223632, https://doi.org/10.1093/rheumatology/keaa383. Content validity pertains to the degree to which the instrument measures all facets of a construct of interest [20]: this property is satisfied if the PGA is considered able to measure all aspects of disease activity in SLE in a comprehensive way. , Roberts WN Bethesda, MD 20894, Web Policies PGA or SGA described in ePROVIDE - Mapi Research Trust Few studies reported on whether serological activity should be incorporated in the PGA. Please enable it to take advantage of the complete set of features! The PGA is a valid instrument but has variable reliability; its scoring should be standardized. , Engle E Clinical composite measures of disease activity and damage used to evaluate patients with systemic lupus erythematosus: A systematic literature review. Pain assessment: An alternative measure - hcplive.com The results are similar, and less than half the time is required for scoring. , Kalunian K Moreover, a difference between the interRR of the PGA assessed by an untrained physician (0.50.63) and a trained investigator (0.790.81) was found, suggesting the need for PGA scoring training or standardization [36]. In a post-hoc analysis of phase 3 belimumab trials, improvements and no worsening in the PGA were greater among SRI responders vs SRI non-responders (P<0.001) [52]. It estimates how similar a given patients scores were at the two visits. , Wallace DJ Physician's Global Assessment in Psoriatic Arthritis: A Multicenter Visual Analog Scale Assessments Can Reliably Assess Disease Severity in SLE The company serves physicians and patients. The PGA intraRR was assessed in three studies [10, 68, 94] and ranged from 0.55 [68] to 0.88 [10]. , Petri M. Thanou A 2022 May;9(1):e000700. For permissions, please email: journals.permissions@oup.com, This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (. , Perneger T Patient global assessment (PGA) is one of the most widely used PROs in RA practice and research and is included in several composite scores such as the 28-joint Disease Activity Score (DAS28). Arriens C Conducting medical monitoring, safety review, narrative writing and etc.. Perform medical assessment of individual . , Hochberg M. Wallace DJ The PGA is a well accepted and commonly used scale for evaluating treatment response in clinical trials both in adults and children. Disclaimer. 2022 Sep 20;19(19):11895. doi: 10.3390/ijerph191911895. , Garabajiu M Associations between physicians' global assessment of disease activity In 89 studies [2, 3, 913, 21102] the PGA was used to measure disease activity as a whole, therefore satisfying the content validity criteria. et al. , Mohan C. Giangreco D Laboratory Investigation Results Influence Physician's Global et al. Touma Z For instance, in an analysis of studies of the prevalence of SLE in the Asia-Pacific region, higher rates of renal involvement were observed in Asian patients (21-65% at SLE diagnosis and 40 . . , Trendelenburg M This week's edition of Faculty Publications includes Cedars-Sinai studies that were published Feb. 23-March 2. Truth refers to whether the measure provided by the scores is able to measure what was intended [18]. Global Automatic Chemiluminescence Immunoassay Analyzer Market 2023 ATI Comprehensive Predictor Exam 2019 (180 Q & A, Verified and 100 In the last 30years, more than a dozen scores have been derived to assess disease activity in SLE, but not all of these have proven to be valid and reliable tools. Introduction Physician global assessments of disease activity (medical doctor (MD) globals) are important outcomes. Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE) - Full , Giannakou I One study, published after our systematic literature search was completed [112], showed that scoring the PGA with knowledge of laboratory data increased its correlation with the SLEDAI-2K (r=0.79) compared with without knowledge of laboratory results (r=0.67). , Oon S Diet and Systemic Lupus Erythematosus (SLE): From Supplementation to Intervention. , Karp DR Can Lupus Patients Take the Driver's Seat in Their Disease Monitoring. , Magder LS et al. Moreover, there is uncertainty as to whether the best timing of assessment is prior to or after reviewing laboratory exams [26]. , Bocci EB All rights reserved. Chaigne B Would you like email updates of new search results? In the absence of a consensus, Aranow [26] found a better correlation between the SLEDAI and the PGA when the latter was assessed taking into account laboratory test results. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, Instrument selection using the OMERACT filter 2.1: the OMERACT methodology, The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes, Health measurement scales: a practical guide to their development and use, A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus, Efficacy and safety of methotrexate in articular and cutaneous manifestations of systemic lupus erythematosus, Performance of SLEDAI-2K to detect a clinically meaningful change in SLE disease activity: a 36-month prospective cohort study of 334 patients, Disease activity patterns over time in patients with SLE: analysis of the Hopkins Lupus Cohort, Comparison of the systemic lupus erythematosus activity questionnaire and the systemic lupus erythematosus disease activity index in a black Barbadian population, A pilot study to determine the optimal timing of the Physician Global Assessment (PGA) in patients with systemic lupus erythematosus, Preliminary test of the LFA rapid evaluation of activity in lupus (LFA-REAL): an efficient outcome measure correlates with validated instruments, Derivation and validation of the SLE Disease Activity Score (SLE-DAS): a new SLE continuous measure with high sensitivity for changes in disease activity, Clinical SLEDAI-2K zero may be a pragmatic outcome measure in SLE studies, Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE, Validation of SIMPLE index for lupus disease activity, Performance characteristics of different anti-double-stranded DNA antibody assays in the monitoring of systemic lupus erythematosus, Psychometric properties of MDHAQ/RAPID3 in patients with systemic lupus erythematosus, Therapeutic adherence in patients with systemic lupus erythematosus: a cross-sectional study, Sensitivity analyses of four systemic lupus erythematosus disease activity indices in predicting the treatment changes in consecutive visits: a longitudinal study, Comparison of the lupus foundation of America-rapid evaluation of activity in lupus to more complex disease activity instruments as evaluated by clinical investigators or real-world clinicians, Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission, Impact of disease activity on health-related quality of life in systemic lupus erythematosusa cross-sectional analysis of the Swiss Systemic Lupus Erythematosus Cohort Study (SSCS), Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study, Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus, Cross-cultural validation of Lupus Impact Tracker in five European clinical practice settings, Failure of a systemic lupus erythematosus response index developed from clinical trial data: lessons examined and learned, Belimumab for the treatment of recalcitrant cutaneous lupus, Progression of noncalcified and calcified coronary plaque by CT angiography in SLE, Impact of heart rate variability, a marker for cardiac health, on lupus disease activity, The lupus impact tracker is responsive to changes in clinical activity measured by the systemic lupus erythematosus responder index, Validation of the Lupus Impact Tracker in an Australian patient cohort, Axl, ferritin, IGFBP2 and TNFR2 as biomarkers in systemic lupus erythematosus, Lupus anticoagulant, disease activity and low complement in the first trimester are predictive of pregnancy loss, Lupus Impact Tracker is responsive to physician and patient assessed changes in systemic lupus erythematosus, Predictors of pregnancy outcomes in patients with lupus: a cohort study, Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials, Validation of the LupusPRO in Chinese patients from Hong Kong with systemic lupus erythematosus, The Swiss Systemic lupus erythematosus Cohort Study (SSCS)cross-sectional analysis of clinical characteristics and treatments across different medical disciplines in Switzerland, How should lupus flares be measured? , Emamikia S , Stavrakis S Barr SG The Patient's Global Assessment Scale (PGA) is the PRO counterpart to the Physician's Global Assessment Scale or Investigator's Global Assessment Scale (PGA-IGA). The Physician Global Assessment (PGA) is an important tool for assessing disease activity in lupus. , Dyer JW Myelogram - correct answer NPO for 4-6 hours. et al. Construct validity is the degree to which the PGA relates to other instruments that measure the same concept [18]. , Koutsoviti S If you have a published paper from this period that does not appear on this list, please contact Sue Marone, who will add it to next week's collection. Content validity. Sullivan KE et al. The literature search identified 91 studies. Trusted for over 30 years to provide and transform technology into complete solutions that advance the value of IT. Bookshelf , Wallace DJ The interobserver agreement between physician (PGA) and patient (PtGA) global assessment for acne and psoriasis was good, reflected by the weighted Cohen (acne, = 0.68; psoriasis, = 0.70) (eTable in the Supplement). Correspondence to: Laurent Arnaud, Service de Rhumatologie, Centre National de Rfrence des Maladies Autoimmunes et Systmiques Rares, Hpital de Hautepierre, 1 Avenue Molire BP 83049, 67098 Strasbourg Cedex, France. RMD Open 2018;4:e000578. Complement-Targeted Therapeutics Market Report (2022 to